197 related articles for article (PubMed ID: 15226762)
1. Circulating enterolactone and risk of breast cancer: a prospective study in New York.
Zeleniuch-Jacquotte A; Adlercreutz H; Shore RE; Koenig KL; Kato I; Arslan AA; Toniolo P
Br J Cancer; 2004 Jul; 91(1):99-105. PubMed ID: 15226762
[TBL] [Abstract][Full Text] [Related]
2. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
Pietinen P; Stumpf K; Männistö S; Kataja V; Uusitupa M; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174
[TBL] [Abstract][Full Text] [Related]
3. Circulating enterolactone and risk of endometrial cancer.
Zeleniuch-Jacquotte A; Lundin E; Micheli A; Koenig KL; Lenner P; Muti P; Shore RE; Johansson I; Krogh V; Lukanova A; Stattin P; Afanasyeva Y; Rinaldi S; Arslan AA; Kaaks R; Berrino F; Hallmans G; Toniolo P; Adlercreutz H
Int J Cancer; 2006 Nov; 119(10):2376-81. PubMed ID: 16929490
[TBL] [Abstract][Full Text] [Related]
4. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Vartiainen E; Sankila R; Virtanen MJ; Adlercreutz H; Pietinen P
Int J Cancer; 2004 Jan; 108(2):277-80. PubMed ID: 14639615
[TBL] [Abstract][Full Text] [Related]
5. Plasma enterolactone and breast cancer risk in the Nurses' Health Study II.
Xie J; Tworoger SS; Franke AA; Terry KL; Rice MS; Rosner BA; Willett WC; Hankinson SE; Eliassen AH
Breast Cancer Res Treat; 2013 Jun; 139(3):801-9. PubMed ID: 23760859
[TBL] [Abstract][Full Text] [Related]
6. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
[TBL] [Abstract][Full Text] [Related]
7. Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period.
Zeleniuch-Jacquotte A; Adlercreutz H; Akhmedkhanov A; Toniolo P
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):885-9. PubMed ID: 9796633
[TBL] [Abstract][Full Text] [Related]
8. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
Piller R; Chang-Claude J; Linseisen J
Eur J Cancer Prev; 2006 Jun; 15(3):225-32. PubMed ID: 16679865
[TBL] [Abstract][Full Text] [Related]
9. An incident case-referent study on plasma enterolactone and breast cancer risk.
Hultén K; Winkvist A; Lenner P; Johansson R; Adlercreutz H; Hallmans G
Eur J Nutr; 2002 Aug; 41(4):168-76. PubMed ID: 12242585
[TBL] [Abstract][Full Text] [Related]
10. Plasma enterolactone and breast cancer incidence by estrogen receptor status.
Olsen A; Knudsen KE; Thomsen BL; Loft S; Stripp C; Overvad K; Møller S; Tjønneland A
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2084-9. PubMed ID: 15598765
[TBL] [Abstract][Full Text] [Related]
11. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.
Stattin P; Adlercreutz H; Tenkanen L; Jellum E; Lumme S; Hallmans G; Harvei S; Teppo L; Stumpf K; Luostarinen T; Lehtinen M; Dillner J; Hakama M
Int J Cancer; 2002 May; 99(1):124-9. PubMed ID: 11948503
[TBL] [Abstract][Full Text] [Related]
12. Serum enterolactone and prognosis of postmenopausal breast cancer.
Buck K; Vrieling A; Zaineddin AK; Becker S; Hüsing A; Kaaks R; Linseisen J; Flesch-Janys D; Chang-Claude J
J Clin Oncol; 2011 Oct; 29(28):3730-8. PubMed ID: 21900115
[TBL] [Abstract][Full Text] [Related]
13. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Virtanen MJ; Adlercreutz H; Albanes D; Pietinen P
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1209-12. PubMed ID: 14652283
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of enterolactone and percentage mammographic density among postmenopausal women.
Stuedal A; Gram IT; Bremnes Y; Adlercreutz H; Veierød MB; Ursin G
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2154-9. PubMed ID: 16172225
[TBL] [Abstract][Full Text] [Related]
15. CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans.
Piller R; Verla-Tebit E; Wang-Gohrke S; Linseisen J; Chang-Claude J
J Nutr; 2006 Jun; 136(6):1596-603. PubMed ID: 16702327
[TBL] [Abstract][Full Text] [Related]
16. Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: assessment of mediation by inflammatory markers.
Jaskulski S; Jung AY; Behrens S; Johnson T; Kaaks R; Thöne K; Flesch-Janys D; Sookthai D; Chang-Claude J
Int J Cancer; 2018 Dec; 143(11):2698-2708. PubMed ID: 29974464
[TBL] [Abstract][Full Text] [Related]
17. The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women.
McCann SE; Moysich KB; Freudenheim JL; Ambrosone CB; Shields PG
J Nutr; 2002 Oct; 132(10):3036-41. PubMed ID: 12368392
[TBL] [Abstract][Full Text] [Related]
18. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study.
Zeleniuch-Jacquotte A; Shore RE; Koenig KL; Akhmedkhanov A; Afanasyeva Y; Kato I; Kim MY; Rinaldi S; Kaaks R; Toniolo P
Br J Cancer; 2004 Jan; 90(1):153-9. PubMed ID: 14710223
[TBL] [Abstract][Full Text] [Related]
19. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study.
Vanharanta M; Voutilainen S; Lakka TA; van der Lee M; Adlercreutz H; Salonen JT
Lancet; 1999 Dec 18-25; 354(9196):2112-5. PubMed ID: 10609816
[TBL] [Abstract][Full Text] [Related]
20. Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis.
Seibold P; Vrieling A; Johnson TS; Buck K; Behrens S; Kaaks R; Linseisen J; Obi N; Heinz J; Flesch-Janys D; Chang-Claude J
Int J Cancer; 2014 Aug; 135(4):923-33. PubMed ID: 24436155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
